成大生物(688739) - 2024 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2024 was CNY 364,709,258.37, representing a year-on-year increase of 3.16%[3] - The net profit attributable to shareholders decreased by 35.88% to CNY 81,463,701.09 compared to the same period last year[3] - The net profit after deducting non-recurring gains and losses fell by 41.09% to CNY 68,349,710.89[3] - The basic and diluted earnings per share both decreased by 35.48% to CNY 0.20[3] - The net profit for Q1 2024 was ¥81,463,701.09, a decrease of 35.9% compared to ¥127,042,894.67 in Q1 2023[20] - Basic and diluted earnings per share for Q1 2024 were both ¥0.20, down from ¥0.31 in Q1 2023[21] - The total operating profit for Q1 2024 was ¥108,021,869.52, a decrease of 28.4% from ¥150,795,939.21 in Q1 2023[20] - The total profit for Q1 2024 was ¥107,967,047.33, down from ¥150,662,556.25 in Q1 2023, reflecting a decline of 28.3%[20] Cash Flow and Liquidity - The net cash flow from operating activities decreased significantly by 69.37% to CNY 33,252,685.73[3] - Cash flow from operating activities for Q1 2024 was ¥33,252,685.73, a decline of 69.4% from ¥108,573,617.95 in Q1 2023[22] - The company reported a decrease in cash outflow for operating activities, totaling ¥336,547,166.65 in Q1 2024, compared to ¥300,635,233.44 in Q1 2023[22] - Cash and cash equivalents as of March 31, 2024, were ¥4,590,885,490.11, slightly up from ¥4,547,961,783.28 at the end of 2023[14] - Total cash and cash equivalents at the end of Q1 2024 increased to ¥4,587,507,490.87 from ¥4,450,628,650.06 at the end of Q1 2023[23] - The beginning balance of cash and cash equivalents was $4,518,812,680.80, down from $5,734,512,816.08 year-over-year[35] - The ending balance of cash and cash equivalents stood at $4,529,524,618.55, showing an increase from $4,419,334,512.81[35] Assets and Liabilities - Total assets at the end of the reporting period were CNY 10,102,561,682.77, a slight increase of 0.21% from the end of the previous year[4] - Total assets as of March 31, 2024, amounted to ¥10,102,561,682.77, compared to ¥10,081,359,085.19 at the end of 2023[16] - The total assets increased to CNY 10,354,782,391.53 in Q1 2024, up from CNY 10,259,680,902.66 in Q1 2023, reflecting a growth of 0.93%[28] - Total liabilities decreased to ¥438,983,610.43 from ¥482,229,845.43 at the end of 2023, indicating improved financial stability[16] - The total liabilities decreased to CNY 296,764,920.13 in Q1 2024, down from CNY 330,557,053.74 in Q1 2023, a reduction of 10.23%[28] Research and Development - Research and development expenses totaled CNY 95,355,544.09, down 16.48% year-on-year, accounting for 26.15% of operating revenue, a decrease of 6.15 percentage points[3] - Research and development expenses increased to ¥58,997,464.13 in Q1 2024, a rise of 33.1% from ¥44,378,770.68 in Q1 2023[19] - Research and development expenses decreased to CNY 19,874,594.47 in Q1 2024 from CNY 38,203,065.95 in Q1 2023, a reduction of 47.96%[31] - The company is focusing on expanding its market presence and investing in new technologies, as indicated by the increase in R&D spending[19] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 27,433[8] - The company has maintained a stable equity position with total equity reaching ¥9,663,578,072.34 as of March 31, 2024, compared to ¥9,599,129,239.76 at the end of 2023[16] - The company's total equity increased to CNY 10,058,017,471.40 in Q1 2024, compared to CNY 9,929,123,848.92 in Q1 2023, reflecting a growth of 1.30%[28] Non-Recurring Gains and Other Income - The company reported non-recurring gains of CNY 13,113,990.20, primarily from government subsidies and investment management income[5] - The company reported a significant increase in cash inflow from investment activities, totaling CNY 675,852,222.70 in Q1 2024 compared to CNY 152,547,164.84 in Q1 2023[34] - The company reported a decrease in financial expenses, with a net financial income of CNY 17,937,668.85 in Q1 2024 compared to CNY 20,676,646.46 in Q1 2023[31] Future Outlook - The company plans to continue focusing on market expansion and new product development to drive future growth[30]